Symansis CEO Dr Peter Foster said the acquisition was a strategic proceed to expand its product offerings and advance both company’s research program and business programs for growth. It allows Symansis to increase its competitive advantage by using excellent proteins in its cell signaling analysis and creates new marketplace opportunities for the company’s antibodies and antibody/protein arrays by leveraging Apollo’s international distribution and sales networks, said Dr Foster. The area of cell signaling study may be the largest and fastest developing in medication research – it has been estimated that around 30 per cent of all drug research is executed in this area. Dr Foster said the worldwide market for antibody/proteins arrays is just about US$500 million a yr with a compounding annual development rate of more than 30 percent.Opponents state some patients may feel pressured to end their lives if doctors are allowed to prescribe fatal medication. Religious groupings have condemned aid-in-dying legislation as against God’s will. Monning is certainly among three Democratic lawmakers who intend to show up with Maynard’s family to promote right-to-die legislation Wednesday. It will be limited to people that have less than half a year to live and requires individuals take deadly medicine themselves without help from a doctor. His costs is modeled off of Oregon’s law, which was authorized by voters in 1994 and reaffirmed in 1997.